MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Sensor-based motor state detection in Parkinson’s disease to approach personalized therapy delivery

    L.P. Roncoroni, M. Scholten, I. Hanci, A. Gharabagi, D. Weiss (Tübingen, Germany)

    Objective: As primary objective, we acquire a data pool of medically-treated PD patients with motor fluctuations to determine the sensitivity and specificity of algorithms capable…
  • 2016 International Congress

    Randomized controlled trial protocol: Balance training with rhythmical cues to improve and maintain balance control in Parkinson’s disease

    T.T.C. Capato, J. Tornai, V.F. Gianguiagi, R.R. Firmino, E.R. Barbosa, M.E. Piemonte (São Paulo, Brazil)

    Objective: Is to evaluate the effects of balance training with rhythmical(BRT) which is a motor program to improve balance associated with rhythmical auditory cues (RACs).…
  • 2016 International Congress

    Utilizing remote blood pressure monitoring in a phase III clinical drug trial for Parkinson’s disease

    J.L. Adams, R.A. Biemiller, K.L. Andrzejewski, S. Sharma, R.L. Rockhill, B.L. Greco, K.C. Hodgeman, P. Singh, S. Khanuja, T. Simuni, K.M. Biglan (Rochester, NY, USA)

    Objective: To determine the feasibility and value of remote blood pressure (BP) monitoring during a clinical trial of isradipine (a dihydropyridine calcium channel antagonist) in…
  • 2016 International Congress

    Therapeutic protocol for Parkinson’s patient with freezing based on action observation plus sonification: Preliminary results

    S. Mezzarobba, M. Grassi, M. Catalan, L. Pellegrini, R. Valentini, B. Krüger, P. Manganotti, P. Bernardis (Trieste, Italy)

    Objective: To evaluate the effects of a novel experimental protocol to treat patients with Parkinson's disease (PwP) and freezing of gait (FoG), using functional, and…
  • 2016 International Congress

    The effects of intensive speech treatment on intelligibility in Spanish dysarthria secondary to Parkinson’s disease

    G. Moya-Gale, E. Levy (New York, NY, USA)

    Objective: To examine the effects of intensive speech treatment (LSVT-LOUD; Ramig et al., 2001) on intelligibility at conversational level in Spanish dysarthria secondary to Parkinson's…
  • 2016 International Congress

    STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort

    T. Simuni, K.M. Biglan, J. Lowell, K. Hodgeman, B. Greco, R. Rockhill, D. Oakes (Chicago, IL, USA)

    Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…
  • 2016 International Congress

    A crossover study of pretarsal and preseptal injections of botulinum toxin type A (BTX-A) in the treatment of hemifacial spasm and blepharospasm

    A. Choolam, K. Kulkantrakorn, P. Lolekha (Pathumthani, Thailand)

    Objective: To compare the efficacy, patient satisfaction, and side effects between pretarsal and preseptal injection sites on BTX-A treatment in abnormal orbicularis oculi contraction in…
  • 2016 International Congress

    Effect of outside influences on the therapeutic benefits of botulinum toxin injections

    D.C. Taylor, P.A. LeWItt, P. Kaminski (Royal Oak, MI, USA)

    Objective: The purpose of this project is to determine if outside influences or stressors have an effect on the therapeutic benefit of botulinum toxin injections…
  • 2016 International Congress

    Copper chelation efficacy of alginate/chitosan based D-penicillamine nanoparticles in rat model of non-Wilsonian brain copper toxicosis

    A. Pal, B.R. Thapa, R.K. Vasishta, R. Prasad (Chandigarh, India)

    Objective: To evaluate the copper (Cu) chelation efficacy of orally administered D-penicillamine loaded nanoparticles to that of conventional D-penicillamine therapy for 90 days in Wistar…
  • 2016 International Congress

    Classification and recommendation of nonpharmacological therapies for Parkinson’s disease

    T.T.C. Capato, C.H. Fen, E.R. Barbosa (São Paulo, Brazil)

    Objective: A multidisciplinary specialized treatment including physiotherapy, speech and language therapy, occupational therapy (OT) associated to the ideal pharmacological treatment and surgical is recommended to…
  • « Previous Page
  • 1
  • …
  • 1727
  • 1728
  • 1729
  • 1730
  • 1731
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley